Related Experiment Video
Updated: Jul 5, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Isolation of the novel phage SAP71 and its potential use against Staphylococcus aureus in an atopic dermatitis mouse
Huaixin Geng1, Xin Yang1, Chenghui Zou2
1Non-Coding RNA and Drug Discovery Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, Sichuan, China.
Abstract:
Atopic dermatitis (AD) is accompanied by changes in skin microbiota, in which abnormal colonization of Staphylococcus aureus is particularly common. The antibiotic treatment is prone to destroy the commensal bacterial community, further exacerbating the microbiome dysbiosis. Elimination of S. aureus through phage-targeted therapies presents a promising method in the treatment strategy of AD. In this study, we isolated a novel phage SAP71, which specifically lysed S. aureus. Genome sequencing showed that SAP71 contained no virulence, lysogenic, or antimicrobial resistance genes, making this lytic phage a potential agent for phage therapy. Moreover, we demonstrated that phage SAP71 was able to significantly improve the skin lesions, reduce the bacterial loads in the skin, and prevent the development of AD-like skin pathological changes in an AD model. In short, phage SAP71 was demonstrated to effectively treat S. aureus infection in AD, which provided a theoretical basis for the clinical phage therapy of AD.
Insights
Novel phage therapy effectively treats Staphylococcus aureus in atopic dermatitis (AD). Phage SAP71, a safe and specific lytic agent, improved skin lesions and reduced bacterial load in an AD model.
Area of Science:
- Microbiology
- Dermatology
- Phage Therapy
Background:
- Atopic dermatitis (AD) is linked to skin microbiome changes, notably Staphylococcus aureus overgrowth.
- Antibiotic treatments disrupt beneficial bacteria, worsening microbiome imbalance in AD.
- Phage therapy offers a targeted approach to eliminate S. aureus without harming commensal bacteria.
Purpose of the Study:
- To isolate and characterize a novel bacteriophage for targeting S. aureus in atopic dermatitis.
- To evaluate the therapeutic potential of the isolated phage in an animal model of AD.
Main Methods:
- Isolation and genomic analysis of a novel bacteriophage, SAP71, targeting S. aureus.
- Assessment of SAP71's lytic activity and safety profile (absence of virulence genes).
- In vivo evaluation of SAP71 efficacy in a mouse model of atopic dermatitis.
Main Results:
- Phage SAP71 was identified as a specific lytic agent against S. aureus.
- Genome sequencing confirmed SAP71 lacks virulence, lysogenic, or antibiotic resistance genes.
- SAP71 treatment significantly improved skin lesions, reduced S. aureus skin burden, and prevented AD-like pathology in the model.
Conclusions:
- Phage SAP71 demonstrates significant therapeutic potential for treating S. aureus infections in atopic dermatitis.
- This study provides a strong preclinical basis for developing phage SAP71 as a clinical therapy for AD.
Related Concept Videos
01:29Staphylococcal Skin Infections
01:25Clinical Significance of Antibiotic Resistance